Elexacaftor/Tezacaftor/Ivacaft
Brand name: Trikafta
Rank #69 of 500 drugs by total cost
$269.3M
Total Cost
9,821
Total Claims
$269.3M
Total Cost
148
Prescribers
$27K
Cost per Claim
850
Beneficiaries
10,041
30-Day Fills
$1.8M
Avg Cost/Provider
66
Avg Claims/Provider
About Elexacaftor/Tezacaftor/Ivacaft
Elexacaftor/Tezacaftor/Ivacaft (sold as Trikafta) was prescribed 9,821 times by 148 Medicare Part D providers in 2023, costing the program $269.3M. At $27K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 66 | Budesonide/Glycopyr/Formoterol (Breztri Aerosphere) | $280.9M | 340,138 |
| 67 | Selexipag (Uptravi) | $279.1M | 12,320 |
| 68 | Liraglutide (Victoza 3-Pak) | $273.0M | 189,358 |
| 69 | Elexacaftor/Tezacaftor/Ivacaft (Trikafta) | $269.3M | 9,821 |
| 70 | Immune Globul G/Gly/Iga Avg 46 (Gamunex-C) | $266.5M | 27,501 |
| 71 | Rosuvastatin Calcium (Rosuvastatin Calcium) | $264.9M | 11,259,701 |
| 72 | Risankizumab-Rzaa (Skyrizi Pen) | $259.7M | 12,539 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology